mt-8421
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2023 (NCT06034860)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- DNA Mismatch Repair · Phase 1
- Esophageal Squamous Cell Carcinoma · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Microsatellite Instability · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06034860 | Phase 1 | Sep 30, 2023 | Molecular Templates |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Molecular Templates | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1